Skp2 Expression is Associated with High Risk and Elevated Ki67 Expression in Gastrointestinal Stromal Tumours

Citation
Di Vizio, Dolores, Francesca Demichelis, Sara Simonetti, Guido Pettinato, Luigi Terracciano, Luigi Tornillo, Michael R. Freeman, and Luigi Insabato. 2008. Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours. BMC Cancer 8: 134.

Published Version
doi:10.1186/1471-2407-8-134

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:5347435

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current/terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours

Dolores Di Vizio1,2, Francesca Demichelis3, Sara Simonetti1, Guido Pettinato1, Luigi Terracciano4, Luigi Tornillo4, Michael R Freeman2,5 and Luigi Insabato*1

Address: 1Department of Functional and Biomorphological Science, University “Federico II”, Naples, Italy, 2Urological Diseases Research Center, Dept. of Urology, Children’s Hospital, Dept. of Surgery, Harvard Medical School, Boston, MA, USA, 3Department of Pathology, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, USA, 4Department of Pathology, University of Basel, Switzerland and 5Dept. of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA

Email: Dolores Di Vizio - Dolores.divizio@childrens.harvard.edu; Francesca Demichelis - frd2004@med.cornell.edu; Sara Simonetti - zosty@hotmail.com; Guido Pettinato - pettinat@unina.it; Luigi Terracciano - lterracciano@uhbs.ch; Luigi Tornillo - ltornillo@uhbs.ch; Michael R Freeman - michael.freeman@childrens.harvard.edu; Luigi Insabato* - Insabato@unina.it

* Corresponding author

Abstract

Background: Gastrointestinal stromal tumors (GIST) exhibit an unpredictable clinical course and can rapidly progress to lethality. Predictions about the biological behavior of GIST are based on a number of canonical clinical and pathologic parameters whose validity in distinguishing between a benign and a malignant tumour is still imperfect. The aim of our study was to investigate the role of morphologic parameters and expression of cells cycle regulators as prognosticators in GIST.

Methods: We performed an immunohistochemical analysis for Ki67, p27KiP1, Jab1, and Skp2, on a Tissue Microarray (TMA) containing 94 GIST. Expression of the above proteins was correlated to classically used prognosticators, as well as to risk groups. Clinical significance of histologic and immunohistochemical features were evaluated in 59 patients for whom follow-up information was available.

Results: Overexpression of Ki67 and Skp2, and p27KiP1 loss directly correlated with the high risk group (p = 0.03 for Ki67 and Skp2, p = 0.05 for p27KiP1). Jab1 expression did not exhibit correlation with risk. In 59 cases provided with clinical follow-up, high cellularity, presence of necrosis, and Ki67 overexpression were predictive of a reduced overall survival in a univariate model. The same parameters, as well as mitotic rate, tumour size, and p27KiP1 loss were indicative of a shortened relapse free survival interval. High cellularity, and high mitotic rate retained their prognostic significance by multivariate analysis.

Conclusion: Our data suggest that a number of histologic parameters in combination with immunohistochemical expression of cell cycle regulators can facilitate risk categorization and predict biologic behavior in GIST. Importantly this study demonstrates, for the first time, that Skp2 expression correlates with Ki67 expression and high risk in GIST.

Published: 13 May 2008

BMC Cancer 2008, 8:134 doi:10.1186/1471-2407-8-134

Received: 24 October 2007
Accepted: 13 May 2008

This article is available from: http://www.biomedcentral.com/1471-2407/8/134
© 2008 Di Vizio et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
GIST are the most frequent non-epithelial tumors of the GI tract. They originate from the interstitial cells of Cajal and are strongly dependent on signaling from the receptor tyrosine kinase (RTK) KIT and the KIT ligand, stem cell factor. Activating mutations in KIT and platelet derived growth factor receptor-A (PDGFRA) result in uncontrolled proliferation and ultimately trigger the onset of GIST [1,2]. Mutations in the kit gene in exons 11, 9, 13 and 17 represent early events in GIST onset and have been associated with malignancy [1,3]. Constitutive activation of RTKs induces expression and/or phosphorylation of a variety of intracellular proteins involved in cell survival, proliferation, and motility and adhesion signals, including components of the PTEN/Pi3K/AKT pathway [4], which modulates cell cycle progression by down-regulation of p27Kip1 in various neoplasms. Reduced expression of PTEN due to mutation is predictive of aggressive disease in human tumors [5]. Low or absent expression of PTEN in GISTs has been found to be associated with clinical progression and poor prognosis [6].

Tumour size and mitotic index play a key role in the grading system for GIST [1,2], although their value in predicting the biological behaviour is limited and all GIST, of any size, can potentially metastasize. To date no single morphologic, immuno-phenotypic or genetic marker can predict the aggressiveness of GIST [1].

The risk classification derived from a 2002 NIH consensus conference provided a means for hierarchical classification of aggressiveness into four categories: very low, low, intermediate and high risk, based on tumour size and mitotic rate [1]. This classification, while conferring essential information on prognostic criteria, still needs to be confirmed by using real follow-up data. In addition, the consensus criteria over-estimate the biologic potential of gastric GIST, in particular that of large tumors with low mitotic rate, as recently reviewed by Miettinen and Lasota [2]. However in general, gastric tumours have a more favourable prognosis than intestinal ones with similar parameters [7].

The proliferation marker Ki67 has proved useful in assessing the rate of tumour cell proliferation in GIST, although it does not seem to be more reliable than mitotic count [8]. Uncontrolled cell growth caused by a reduction of levels of cyclin-dependent kinase inhibitors (CKI) is a key event in human tumour evolution [9]. Loss of p27Kip1 correlates with aggressive potential in human carcinomas [10], and sarcomas [11], and is an independent prognostic factor in other human tumours [12]. Published evidence suggests a more general deregulation of the cell cycle in GIST, and we have recently reported that p16INK4A loss can identify high risk GIST [13], in agreement with data from a separate study [14]. p27Kip1 loss has been associated with malignant potential in some reports on GIST [15-17], although its value as a prognostic marker has not been conclusively determined in this tumour type [18]. The human Jun activation-binding protein 1 (Jab1) has been identified as a p27Kip1 interacting protein, that induces nuclear export of p27Kip1 to the cytoplasm, thus permitting its degradation via the ubiquitin-proteasome pathway [19], and in particular by the activation of the SCF-Skp2/E3 ubiquitin protein ligase pathway [20]. The F-Box protein Skp2 functions as the substrate recognition factor of the SCF complex, which recognizes and binds to phosphorylated p27Kip1 [21]. Recent findings indicate that p27Kip1 contributes to Skp2 inhibition via a mechanism that involves repression of target gene promoter activity, suggesting a reciprocal regulation between the two proteins [22]. Skp2 overexpression plays a role as an independent prognosticator, stronger than p27Kip1 and Ki67, in soft tissues sarcomas [23]. To the best of our knowledge, its significance as a prognostic marker in GIST has not been investigated.

The role of Jab1 in human oncogenesis is currently under investigation. Tomoda et al. showed that Jab1 physically interacted with p27Kip1 and enhanced its cytoplasmic translocation, which resulted in accelerated degradation of p27Kip1 via the ubiquitin/proteasome pathway [19]. Data on human tumours demonstrate that p27Kip1 expression is inversely correlated to Jab1 expression [24], and recently Jab1 expression has been demonstrated to induce p27Kip1 degradation by a Skp2 independent mechanism in pancreatic carcinoma cells [25].

In this study we have evaluated the significance of histologic parameters and expression of cell cycle regulators in 94 GISTs, 59 of which with clinical information. Our data confirm the importance of using a mixture of histologic and immunohistochemical parameters in order to predict potential benign or malignant behavior in a given GIST at diagnosis. They also point out to a role for Skp2 and p27Kip1 as prognostic indicators, in GIST, of good or bad behavior respectively.

Methods
Clinico-pathologic evaluation
Sample collection, tumour localization, assessment of behavior, and TMA construction have been described in detail elsewhere [3]. Two pathologists (DDV and LI) re-examined representative slides of each tumour. The diagnosis of GIST was confirmed in case of a mesenchymal spindle cell or epithelioid tumour of the GIST showing unequivocal positivity for CD117. 94 patients met these criteria and were included in this study. The 94 GIST patients comprised 50 males and 44 females with a mean age of 61 years (range 26–91, SD 14). Tumour localiza-
Morphologic features of GISTs. A) Spindle cell tumor infiltrating the submucosa and lamina propria of the colon. B) Epithelioid cell type tumor. C) Malignant GIST with prominent pleomorphism and high mitotic activity. D) Nuclear palisade feature of GISTs. E) Numerous scattered and patchy tumor infiltrating lymphocytes. F) Strong immunoeexpression of CD 117.
groups were dichotomized to Group A and B, comprising A) very low and low risk, B) intermediate, high risk, and malignant tumours. Tumour size was dichotomized (group 1 ≤ 5 cm, group 2 > 5 cm).

**Ethical approval**
Institutional Review Board approval was obtained before the initiation of this study.

**Results**

**Pathological findings**
Grossly the tumors were variable in shape. Some were well circumscribed, firm and whitish, with an irregularly whorled cut-surface. Others showed ill-defined outlines, soft or fleshy consistency, with necrotic or hemorrhagic areas. Microscopically the tumors were categorized as spindle or epithelioid depending on the most represented cell type (> 50%) throughout the tumor. Thus 44 tumors (47%) were predominantly composed of spindle cells (Fig 1A), 13 tumors (14%) of epithelioid cells (Fig 1B), and 37 tumors (39%) of both cell types, mixed in variable proportions. 30 cases of gastric tumors showed the characteristic perinuclear cytoplasmic vacuoles, whereas skeinoid fibers were seen in 3 tumors located in the small bowel. Other peculiar histologic features are represented in Fig. 1C–E. The categorization of risk was as follows: follow-up was available in 59/94 cases. 23 of them were considered clinically malignant (12 died of disease and 11 were alive with metastatic/recurrent disease). Of the 36 cases with known follow-up remaining, 35 were alive with metastatic/recurrent disease. Of the 57 cases for which clinical data were lacking. Of these 71 cases (36+35) 14 had metastasis at time of diagnosis or later and therefore were considered also malignant. Therefore 37 cases (23+14) were considered as "malignant". The remaining 57 cases were categorized according to the NIH consensus: 12 cases were considered high risk tumours, 19 tumours were intermediate risk, 21 tumours were low risk, and 5 tumours were categorized as very low risk. Surveys for the presence of tumour-infiltrating lymphocytes (TIL) revealed a low amount of TIL in 2 tumours, moderate amounts in 28 tumours and numerous TIL in 5 tumours. Of all histological parameters, mitosis (\(p = 0.001\)), necrosis (\(p = 0.02\)), and tumour size (\(p < 0.001\)) significantly correlated with risk groups dichotomized to two categories (A & B). The presence of giant cells did not exhibit any correlation with other parameters.

**Immunohistochemical findings**
All tumours displayed strong immunoreactivity for CD117. The staining was localized in the cytoplasm, with either a granular or homogeneous quality (Fig 1F). Some differences of immunoreactivity were observed. In particular, in gastric tumours, CD34, Desmin and Smooth Muscle Actin (SMA) were positive in 98%, 9% and 41% of the samples respectively; while in extra-gastric tumours, they were positive in 65%, 0% and 56% of the samples.

**Cell cycle protein expression**
Detailed results are summarized in Table 2 and Table 3. Ki67 nuclear expression, higher than 10%, was identified in 21 tumours (19.7%), and significantly correlated with high risk (\(p = 0.03\)). p27kip1 nuclear expression, in more than 50% of the cells, was detected in 16 tumours (15%) and was significantly higher in low-risk than in high-risk neoplasms (\(p = 0.04\)). Skp2 expression was detected in 24 tumours (32%), significantly higher in high risk tumours (\(p = 0.03\)). Representative examples of p27kip1, Skp2, Jab1, and Ki67 staining are displayed in Fig 2. Jab1 expression was detected in 39 (36.6%) of the tumours and did not exhibit correlation with risk (data not shown). p27kip1 levels were directly and significantly correlated with Jab1 levels (\(p < 0.01\)), and an indirect trend of correlation was seen with Skp2 levels, even though this was not significant (data not shown). Interestingly Skp2 expression correlated with cellularity (\(p = 0.05\)), tumour size (\(p = 0.01\)), mitotic count (\(p = 0.05\)) and Ki67 (\(p = 0.01\)) (Table 3).

---

**Table 1: Primary antibodies for immunohistochemical analysis**

| Antibody | Clone | Manufacturer | Retrieval | Dilution | Method |
|----------|-------|--------------|-----------|----------|--------|
| CD117    | Polyclonal | DAKO, Carpinteria, CA, USA | Steam 120°/3' Cytrate buffer pH 6 | 1:300 | ABC   |
| CD34     | QBEND10 | DAKO, Carpinteria, CA, USA | Microwave 98°/60' Cytrate buffer pH 6 | 1:900 | ABC   |
| CK22     | Cytokeratin | Biomedan, San Francisco, CA, USA | Microwave 98°/60' Cytrate buffer pH 6 | 1:400 | ABC   |
| Desmin   | D33 | DAKO, Carpinteria, CA, USA | Cook 15° Cytrate buffer pH 6 | 1:200 | ABC   |
| SMA      | IA4 | Sigma, Saint Louis, MO, USA | Microwave 80°/30' Cytrate buffer pH 6 | 1:60000 | ABC   |
| S-100    | Polyclonal | DAKO, Carpinteria, CA, USA | Microwave 80°/30' Cytrate buffer pH 6 | 1:10000 | ABC   |
| NSE      | BBS/NC/VI | DAKO, Carpinteria, CA, USA | Cook 15° Cytrate buffer pH 6 | 1:8000 | ABC   |
| Ki67     | MIB-1 | DAKO, Carpinteria, CA, USA | Microwave 98°/60' Cytrate buffer pH 6 | 1:16000 | ABC   |
| p27kip1  | 57 | BD Transduction Laboratories, Lexington KY, USA | Microwave 98°/60' Cytrate buffer pH 6 | 1:500 | ABC   |
| Jab-1    | Polyclonal | Santa Cruz Biotechnology, Santa Cruz, CA, USA | Microwave 98°/60' Cytrate buffer pH 6 | 1:200 | ABC   |
| Skp2     | 2C8D9 | Zymed LAB, San Francisco, CA, USA | Microwave 98°/60' Cytrate buffer pH 6 | 1:100 | ABC   |
Clinico-pathological correlations and prognosis (Survival analysis)

The median follow-up period for the patients with GIST was 46 months (maximum 177, minimum 4). Medical charts were available in 59 cases of 94 patients (63%). Of these 59 patients, 11 (19%) died of disease, and 12 (21%) were alive with recurrent/metastatic disease. These 23 tumours were considered clinically malignant. An additional 35 patients (60%) were alive without disease, and 1 (2%) died from other causes. Univariate analysis was performed for patient age, tumour localization in the GI tract, tumour size, cellularity, cell type, mitosis, necrosis, risk grade, p27Kip1, Skp2, Jab1 and Ki67 expression. Of the above parameters, we found that necrosis (p = 0.01), high cellularity (p = 0.04) and Ki67 overexpression (p = 0.04) were significantly associated with reduced overall survival (OS). The best multivariate model included cellularity (p = 0.02) (data not shown). Cellularity (p = 0.01), mitosis (p < 0.001), tumour size (p = 0.01), high risk (p = 0.01), Ki67 (p = 0.02), and p27Kip1 (p = 0.05) were significantly associated with reduced relapse free survival (RFS), by univariate analysis, as showed in Table 4. The Kaplan-Meier curves relative to cellularity and Ki67 expression are represented in Fig 3 and 4 respectively. TIL was associated with RFS, approaching statistical significance (data not shown).

Discussion

Our results, on a TMA containing 94 primaries GIST, show that morphological parameters and immunohistochemical markers, alone and in combination, may be useful in predicting benign or malignant biologic behavior of GIST at diagnosis. In particular, our analysis of 59 cases, for which clinical information was available, suggests 1) an independent role for high cellularity in predicting reduced OS; 2) a significant correlation of cellularity, mitosis, tumour size, high risk, Ki67 expression, and p27Kip1 expression with RFS; 3) a direct correlation of p27Kip1 loss as well as of Ki67 and Skp2 over expression with high risk; and 4) a significant correlation between Ki67 over expression and OS.

High cellularity, mitosis, and tumour size have been demonstrated to be prognostic factors in separate studies [2,8,27]. Our results confirm the validity of the above classical morphological parameters in attributing potentially malignant behaviour to a given tumour.

We also analyzed the tumours for the presence of TIL. We found a trend toward an inverse correlation between the presence of TIL and shortened RFS. TIL are the primary immune component infiltrating solid tumours and are considered to be a manifestation of the host anti-tumour reaction. To the best of our knowledge this feature, only analyzed in one recent report [28], has not been identified as a histologically significant indicator in GIST. Our data not only suggest a role for TIL in an anti-tumour reaction, but also suggest further investigation on additional series, into whether GIST patients might be identified who could benefit from immunotherapy.

In our study, Ki67 over-expression significantly correlated with high risk and with both OS and RFS. These data are in apparent contradiction with a study attributing a stronger potential to mitotic rate than Ki67 index as a prognosticator in GIST [15], however they are consistent with other studies in which Ki67 labeling index (LI) discriminated between potentially benign and malignant GIST better than counts of mitotic figures [8]. The direct correlation between expression of Ki67 and Skp2 was significant, in agreement with what has been found in several tumour types, including mesenchymal neoplasms [23,29,30].

Table 2: Clinicopathologic parameters and risk categories

| VARIABLE | Group A | Group B |
|----------|---------|---------|
| N° cases | 26      | 68      |
| Sex      | M       | 15      |
|          | F       | 11      |
| Cell type| Spindle | 8       |
|          | Epithelioid | 4   |
|          | Mixed   | 14      |
| Cellularity | Low     | 15      |
|          | High    | 11      |
| Necrosis | 0       | 26      |
|          | 1       | 20      |
| Mitosis  | 1       | 21      |
|          | 2       | 5       |
| Metastases|         | 1       |
| p27Kip1 (%) | 9/26 (34.6%) | 7/50 (14%) |
| Skp2 (%)   | 4/25 (16%) | 20/50 (40%) |
| Jab1 (%)   | 16/25 (64%) | 23/48 (47.9%) |
| Ki67 (%)   | 3/25 (12%) | 18/52 (34.6%) |

Necrosis: 0 = absent; 1 = present
Mitosis: 1 ≤ 5 × 50 HPF; 2 > 5 × 50 HPF
Cellularity: Low cellularity ≤ 100 tumor cells × 10 HPF; High cellularity > 100 tumor cells × 10 HPF

Table 3: Correlation between morphologic criteria and cell cycle regulators

| VARIABLE | p27Kip1 | Ki67 | Skp2 |
|----------|---------|------|------|
| Cellularity | 1       | < 0.001* | 0.05* |
| Mitotic count | 0.34    | 0.01* | 0.05* |
| Necrosis    | 0.26    | 0.08  | 0.82 |
| Risk groups (A&B) | 0.04* | 0.03* | 0.03* |
| Tumor size  | 0.27    | 0.64  | 0.01* |

* Statistically Significant

(p < 0.001), tumour size (p = 0.01), high risk (p = 0.01), Ki67 (p = 0.02), and p27Kip1 (p = 0.05) were significantly associated with reduced relapse free survival (RFS), by univariate analysis, as showed in Table 4. The Kaplan-Meier curves relative to cellularity and Ki67 expression are represented in Fig 3 and 4 respectively. TIL was associated with RFS, approaching statistical significance (data not shown).
In this study p27Kip1 loss was significantly correlated with the degree of malignancy of GIST. The role of p27Kip1 expression as a diagnostic or prognostic marker for a broad series of human tumours is currently under intense investigation. Our results are in agreement with a number of published studies [16,31,32]. In particular Gelen et al. demonstrated that p27Kip1 expression is correlated to RFS [31]. p27Kip1 loss has not been conclusively associated with biological aggressiveness of GIST, and is not used as a predictor of survival [15,17,18]. Our results, obtained on a larger series, show an association between p27Kip1 loss and RFS, suggesting an important role for p27Kip1 in the progression of GIST, and urging further investigation of its potential as a prognostic marker.

Cell cycle progression in mammalian cells is finely regulated by the sequential activation of a cascade of cyclin-dependent kinases, which are modulated by a complex series of interactions between cyclins and cyclin-dependent kinases inhibitors (CKIs). p27Kip1 is a specific CKI present at high abundance in quiescent cells and is a putative tumour suppressor [11,33]. While loss of function of tumour suppressors occurs frequently at the genetic level, p27Kip1 mutations represent an extremely rare event, consistent with data that p27Kip1 expression is regulated at the post-transcriptional level [34].

In our study, Skp2 expression significantly correlated with cellularity, high risk, tumour size, mitotic count, and Ki67 expression. To our knowledge, the significance of Skp2 over-expression as a prognostic marker in GIST has not been previously investigated. We found an inverse correlation between levels of Skp2 and p27Kip1, which approached the statistical significance. These data are in agreement with studies on lymphomas [35] and colorectal cancer [10] and suggest that over-expression of Skp2 contributes to p27Kip1 degradation in GIST. Our data are

### Table 4: Univariate analysis of various parameters for Overall Survival (OS) and Release Free Survival (RFS).

| VARIABLE         | OS   | RFS  |
|------------------|------|------|
| Cell Type        | 0.42 | 0.27 |
| Cellularity      | 0.04*| 0.00*|
| Mitotic count    | 0.09 | 0.00*|
| Necrosis         | 0.01*| 0.14 |
| Risk groups (A&B)| 0.07 | 0.01*|
| Tumor size       | 0.13 | 0.01*|
| p27Kip1          | 0.42 | 0.05 |
| Ki67             | 0.04*| 0.02*|
| Skp2             | 0.43 | 0.5  |

* Statistically Significant
in contrast with findings by Oliveira et al [23] in soft tissues sarcomas, which suggest the possibility of an alternative mechanism for p27\(^{kip1}\) degradation in sarcomas. Skp2 over-expression plays a role in aggressiveness of soft tissues sarcomas, where it has been found to be an independent prognosticator, stronger than p27\(^{kip1}\) and Ki67 [23]. In our study, Skp2 over-expression did not correlate with OS and RFS. However, the correlation of Skp2

![Graphs showing Kaplan-Meier curves for cellularity and Ki67 analysis related to overall survival and relapse-free survival.](image)

**Figure 3**
Kaplan-Meier curves of cellularity with respect to overall survival and relapse free survival, respectively. The p-value of the log-rank test is reported for each curve.

![Graphs showing Kaplan-Meier curves for Ki67 analysis related to overall survival and relapse-free survival.](image)

**Figure 4**
Ki67 Kaplan-Meier analysis with respect to overall survival and relapse free survival, respectively. The p-value of the log-rank test is reported for each curve.
expression with several parameters of malignant potential (cellularity, high risk, tumour size, mitotic count, and Ki67 expression) suggests an important auxiliary role of Skp2 in predicting the aggressive potential of GIST.

The role of Jab1 in human oncogenesis is currently under investigation. Recently Jab1 expression, inversely correlated to p27Kip1 expression in pancreatic carcinoma and has been demonstrated to induce p27Kip1 degradation by a Skp2-independent mechanism [25]. In our series, Jab1 expression did not correlate with any of the other parameters we analyzed, including p27Kip1 expression, suggesting that degradation of p27Kip1 in GIST might be Jab1-independent. It would be interesting to test this hypothesis using in vitro systems.

Conclusion
We demonstrated in the current study that p27Kip1 loss and Skp2 over-expression correlate with high risk grade in GIST. Additional studies are necessary to clarify their role as prognostic indicators.

Competing interests
The study was funded by Novartis-Stiftung für medizinisch-biologische Forschung.

The authors declare that there are no other competing interests

Authors' contributions
DDV designed the study, performed the immunohistochemical assay, analyzed the histologic and immunohistochemical results, and helped to draft the manuscript. FD performed the statistical analysis, and along with SS, helped to draft the manuscript. LTE, GP, LTO and MRF participated in the design of the study and MRF edited the manuscript. LI conceived the study, analyzed the histologic and immunohistochemical results, and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors are grateful to Drs. R. Russo, A. Boscaino, O. Nappi, A. Di Blasi, for providing their collection of tumours for this study, and to Dr. S. Masone for providing clinical information. The authors thank Mr. A. Coppola and P. Signorillo for their kind technical assistance. DDV is an American Italian Cancer Foundation (AICF) fellow. Particular thanks to Stiftung Novartis für medizinisch-biologische Forschung for their support.

References
1. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002, 10(2):81-89.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006, 130(10):1466-1478.
3. Tornillo L, Duchini G, Carafa V, Lugli A, Dinhirof S, Di Vizio D, Boscaino A, Russo R, Tapia C, Schneider-Stock R, Sauter G, Insabato L, Terracciano L. Pattern of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest 2005, 85(7):921-931.
4. Sun H, Lesche R, Li DM, Lilienatl J, Zhang H, Gao J, Gavrilo N, Mueller B, Liu X, Wu H: PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A 1999, 96(11):6199-6204.
5. Di Vizio D, Cito L, Boccia A, Chiiffei P, Insabato L, Pettinato G, Motti ML, Schepis F, D’Amico W, Fabiani F, Tavernise B, Venuta S, Fusco A, Viggioso G. Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene 2005, 24(11):1882-1894.
6. Ricci R, Maggiano N, Castri F, Rinali M, Murazito M, Pacelli F, Potenza AE, Vecchio FM, Larocca LM. Role of PTEN in gastrointestinal stromal tumor progression. Arch Pathol Lab Med 2004, 128(4):421-425.
7. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006, 23(2):70-83.
8. Wong NA, Young R, Malcomson RD, Nayar AG, Jamieson LA. Save VE, Carey FA, Brewster DH, Han C, Al-Nafussi A: Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003, 43(2):118-126.
9. Baghdassarian N, Frischen M. Cyclin-dependent kinase inhibitors (CKIs) and hematological malignancies. Hematol Cell Ther 1996, 38(4):313-323.
10. Hershko DD, Shapira M: Prognostic role of p27Kip1 deregulation in colorectal cancer. Cancer 2006, 107(4):668-675.
11. Goto Y, Kawouchi S, Ibata K, Ikamoto K, Obi R, Kawai S, Sasaki K: The prognosis in spindle-cell sarcoma depends on the expression of cyclin-dependent kinase inhibitor p27(Kip1) and cyclin E. Cancer Sci 2003, 94(5):412-417.
12. Salerno G, Di Vizio D, Staibano S, Mortola G, Quarenghi G, Muscolo M, Galli V, De Rosa G, Insabato L. Prognostic value of p27Kip1 expression in Basaloid Squamous Cell Carcinoma of the larynx. BMC Cancer 2006, 6:146.
13. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P, Terracciano L, Pross M, Insabato L, Di Vizio D, Isailnieks I, Dinhirof S, Hartmann A, Heinrich M, Miettinen M, Roessner A, Tornillo L. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 2005, 11(2 Pt 1):638-645.
14. Ricci R, Arora V, Castri F, Murrini M, Maggiano N, Murazito M, Pacelli F, Potenza AE, Vecchio FM, Larocca LM. Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol 2004, 122(1):35-43.
15. Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, Yamada T, Nawata H, Tsuneyoshi M: Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 2005, 36(7):828-837.
16. Sabah M, Cummins R, Leader M, Kay E: Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: markers with potential prognostic implications. Hum Pathol 2006, 37(6):648-655.
17. Pruner G, Mazzarol G, Fabris S, Del Curto B, Bertolli F, Neri A, Viale G: Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation. Mod Pathol 2003, 16(9):886-892.
18. Shirin H, Kravstov V, Shahrroum M, Shabat VS, Krinshpon I, Alin A, Avinoach I, Avni Y: The cyclin-dependent kinase inhibitor, p27, has no correlation with the malignant potential of GIST. Digestion 2007, 75(1):4-9.
19. Tomoda K, Kubota Y, Arata Y, Mori S, Maeda M, Tanaka T, Yoshida Y, Isono K, Kato Y, Matsumoto T, Fujisawa M: Immunohistochemical study of expression of cyclin-dependent kinase inhibitor p27kip 1 and the cyclin D3 gene in gastrointestinal stromal tumors. Cancer 2003, 97(12):3240-3246.
of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. *Pathol Int* 2004, 54(9):675-681.

21. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. *Science* 1995, 269(5224):682-685.

22. Hulit J, Lee RJ, Li Z, Wang C, Kastyar S, Yang J, Quong AA, Wu K, Albaneese C, Russell D, Di Vizio D, Koff A, Thummla S, Zhang H, Harrell J, Sun H, Muller WJ, Inghirami G, Lansier MP, Pessell RG: p27Kip1 Repression of ErbB2-Induced Mammary Tumor Growth in Transgenic Mice Involves Skp2 and Wnt(βeta)-Catenin Signaling. *Cancer Res* 2006, 66(17):8529-8541.

23. Oliveira AM, Okuno SH, Nascimento AG, Lloyd RV: Skp2 protein expression in soft tissue sarcomas. *J Clin Oncol* 2003, 21(4):722-727.

24. Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Clare FX: Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27Kip1. *Cancer Res* 2003, 63(11):2977-2981.

25. Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chao P, Ho L, Evans DB, Clare FX: Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27Kip1 in pancreatic adenocarcinoma. *Cancer Res* 2006, 66(17):8581-8589.

26. Onguc H, Yilmazlar T, Yerci O, Soylu R, Tumay V, Filiz G, Zorluoglu A: Analysis of prognostic and immunohistochemical factors in gastrointestinal stromal tumors with malignant potential. *J Gastrointest Surg* 2005, 9(3):418-429.

27. Daum O, Grossmann P, Vanek T, Sima R, Mukanenstabl P, Michal M: Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. *Ann Diagn Pathol* 2007, 11(1):27-33.

28. Bertin M, Angriam I, Scarpa M, Menicari R, Ranzato R, Ruffolo C, Poles L, Iacobone M, D’Amico DF: Prognosis of gastrointestinal stromal tumors. *Hepatobiliarypancreatol* 2007, 54(73):124-128.

29. Pennin RM, Fernandez-Gameas MT, Puig L, Rer J, Ferrardiz C, Ariza A: Over-expression of p53(SKP2) in Kaposi’s sarcoma correlates with higher tumor stage and extracutaneous involvement but is not directly related to p27(KIP1) down-regulation. *Mod Pathol* 2002, 15(1):127-135.

30. Li JQ, Wu F, Masaki T, Kudo A, Fujita J, Dixon DA, Beauchamp RD, Ishida T, Kurinami S, Imura K: Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors. *Int J Oncol* 2004, 25(1):87-95.

31. Gelen T, Elpek GO, Aksoy NH, Ogus M, Keles N: p27 Labeling index and proliferation in gastrointestinal stromal tumors: correlations with clinicopathologic factors and recurrence. *Jpn J Clin Oncol* 2003, 33(7):346-352.

32. Nemoto Y, Mikami T, Hana K, Kikuchi S, Kobayashi N, Watanabe M, Okayasu I: Correlation of enhanced cell turnover with prognosis of gastrointestinal stromal tumors of the stomach: relevance of cellularity and p27kip1. *Pathol Int* 2006, 56(12):724-731.

33. Gruninger M, Wang Y, Mardel T, Cilenese Z, Keidel EM, Waddell MB, Jakel H, Kullmann M, Kriwacki RW, Hengst L: Cdk-inhibitory activity and stability of p27kip1 are directly regulated by oncogenic tyrosine kinases. *Cell* 2007, 128(2):269-280.

34. Carrano AC, Eytan E, Hershko A, Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. *Not Cell Biol* 1999, 1(4):193-199.

35. Luttrell E, Charle P, Schulten SA, Pavlech NP, Pellicer A, Inghirami G, Pagano M: Role of the F-box protein Skp2 in lymphomagenesis. *Proc Natl Acad Sci U S A* 2001, 98(5):2515-2520.

**Pre-publication history**

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/8/134/prepub